Tumour lysis syndrome (TLS)
Protocol · Haematology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Oncologic emergency — massive tumour-cell lysis dumps K⁺, phosphate and purines (→ urate): hyperkalaemia + hyperphosphataemia + hyperuricaemia + secondary hypocalcaemia, with AKI and arrhythmia. Classically 3 days before to 7 days after starting chemo, but also with steroids alone, rituximab/obinutuzumab, venetoclax, CAR-T or spontaneously.
Assessment
Investigations
- Highest risk: Burkitt / ALL / aggressive NHL, high-WBC AML, CLL on venetoclax; bulky >10 cm or WBC >50k, LDH >2× ULN, urate >7.5 mg/dL, pre-existing renal impairment
- Cairo–Bishop laboratory TLS = ≥2 of: urate ≥8 mg/dL (476 µmol/L), K⁺ ≥6 mmol/L, phosphate ≥4.5 mg/dL, corrected Ca ≤7 mg/dL (1.75 mmol/L) — each ≥ULN or ≥25% rise. Clinical TLS = that + AKI (creatinine ≥1.5× ULN), arrhythmia/sudden death or seizure
- U&E, urate, phosphate, corrected/ionised calcium, LDH, VBG; continuous ECG; Ca×PO₄ product >60 mg²/dL² raises AKI risk
Management
- Aggressive IV fluids to drive a high urine output; close electrolyte monitoring + cardiac monitor
- High-risk → rasburicase 0.2 mg/kg (urate oxidase; preferred) — CONTRAINDICATED in G6PD deficiency (haemolysis/metHb); lower-risk → allopurinol 300 mg/day (prevents new urate only)
- Treat hyperkalaemia (calcium, insulin–dextrose, salbutamol) and hyperphosphataemia (binders); give calcium only for symptomatic hypocalcaemia (it can worsen Ca-phosphate deposition); do NOT routinely alkalinise urine
- Renal replacement therapy for refractory hyperkalaemia, fluid overload, severe uraemia or Ca×PO₄ ≥70; early nephrology + haematology
Disposition
Clinical TLS (AKI, arrhythmia, seizure) → monitored bed/ICU + nephrology. High-risk malignancies need prophylaxis (fluids + rasburicase/allopurinol) and monitoring before and during treatment.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.